SilkTech Biopharmaceuticals
VC-backed biotech Company with several patented silk protein-derived anti inflammatory therapies in FDA Clinical Trials.
VC-backed biotech Company with several patented silk protein-derived anti inflammatory therapies in FDA Clinical Trials.
Silk Technologies Analysis
Silk Technologies is a biotechnology startup dedicated to innovating silk-derived solutions for healthier eyes. Founded in 2013, the company focuses on creating and advancing silk-derived protein (SDP) solutions for eye care, particularly for the treatment of dry eye disease.
Silk Technologies' proprietary SDP material has garnered attention and support from various sources, including angel investors, grants, and a recent funding round. Notably, the company secured a $6.20M Series B investment on 16 April 2019, led by Skyview Ventures.
Based in Plymouth, MN, Silk Technologies operates at the intersection of biotechnology and healthcare, positioning itself at the forefront of innovative treatments for eye-related conditions.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | $6.20M | 1 |
|
16 Apr 2019 |
| Series A | $11.00M | 1 |
|
01 Oct 2017 |
No recent news or press coverage available for SilkTech Biopharmaceuticals.
We care about your data, and we'd love to use cookies make your experience better.
